Solid Biosciences Llc Stock Analysis

Solid Stock Analysis Notes

About 99.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.91. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Solid Biosciences LLC recorded a loss per share of 2.48. The entity had not issued any dividends in recent years. The firm had 1:15 split on the 28th of October 2022. Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts. Solid Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 104 people. To find out more about Solid Biosciences LLC contact Alexander Cumbo at 617 337 4680 or learn more at https://www.solidbio.com.

Solid Biosciences LLC Investment Alerts

Solid Biosciences LLC Upcoming and Recent Events

Solid Largest EPS Surprises

View All Earnings Estimates

Solid Biosciences Environmental, Social, and Governance (ESG) Scores

Solid Stock Institutional Investors

Note, although Solid Biosciences' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Solid Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 427.73 M.

Solid Profitablity

Management Efficiency

Solid Biosciences LLC has return on total asset (ROA) of (0.4367) % which means that it has lost $0.4367 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8683) %, meaning that it created substantial loss on money invested by shareholders. Solid Biosciences' management efficiency ratios could be used to measure how well Solid Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of January 7, 2026, Return On Tangible Assets is expected to decline to -0.8. In addition to that, Return On Capital Employed is expected to decline to -0.99. At present, Solid Biosciences' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Asset Turnover is expected to grow to 0.05, whereas Total Assets are forecasted to decline to about 157.6 M.

Technical Drivers

As of the 7th of January, Solid Biosciences has the Risk Adjusted Performance of 0.0178, coefficient of variation of 7974.8, and Semi Deviation of 5.07. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Solid Biosciences LLC, as well as the relationship between them.

Solid Biosciences LLC Price Movement Analysis

Solid Biosciences LLC Insider Trading Activities

Solid Biosciences Outstanding Bonds

Solid Biosciences Predictive Daily Indicators

Solid Biosciences Corporate Filings

Solid Biosciences Forecast Models

Solid Biosciences' time-series forecasting models are one of many Solid Biosciences' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Solid Biosciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Solid Biosciences LLC Debt to Cash Allocation

Solid Biosciences LLC currently holds 24.18 M in liabilities with Debt to Equity (D/E) ratio of 0.15, which may suggest the company is not taking enough advantage from borrowing. Solid Biosciences LLC has a current ratio of 7.69, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Solid Biosciences' use of debt, we should always consider it together with its cash and equity.

Solid Biosciences Total Assets Over Time

Solid Biosciences Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Solid Biosciences uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Solid Biosciences Debt Ratio

5.85

It appears most of the Solid Biosciences' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Solid Biosciences' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Solid Biosciences, which in turn will lower the firm's financial flexibility.

Solid Biosciences Corporate Bonds Issued

Solid Net Debt

Stock analysis is the technique used by a trader or investor to examine and evaluate how Solid Biosciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Solid shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Solid Biosciences. By using and applying Solid Stock analysis, traders can create a robust methodology for identifying Solid entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Solid analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Solid analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Solid Biosciences LLC stock analysis indicators help investors evaluate how Solid Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Solid Biosciences shares will generate the highest return on investment. By understating and applying Solid Biosciences stock analysis, traders can identify Solid Biosciences position entry and exit signals to maximize returns.

When running Solid Biosciences' price analysis, check to measure Solid Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Solid Biosciences is operating at the current time. Most of Solid Biosciences' value examination focuses on studying past and present price action to predict the probability of Solid Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Solid Biosciences' price. Additionally, you may evaluate how the addition of Solid Biosciences to your portfolios can decrease your overall portfolio volatility.